Are you looking for lead candidate compounds for your target and do you want your drug discovery program to be more efficient, in terms of both time and cost?
Pivot Park Screening Centre (PPSC) is your optimal partner in early drug discovery.
Projects are tailored to your requirements; We provide drug discovery services in the fields of biochemical and cellular assay development, lab automation, Ultra-High-Throughput Screening (uHTS, usually in 1536-well format) and hit-to-lead biological profiling, in order to find novel leads for drug development.
All major read-out modalities are available in-house ensuring rapid generation of high-quality hits. As first CRO we integrated Mass Spectrometry (MALDI-TOF MS) into our uHTS system.
You can either bring your own compound library or use our 300K IP-free druglike compound library. Our fully automated robot system can handle over 1 mln compounds per screen. The past 10 years we have successfully completed more than 150 screening campaigns.
We are continuously expanding our early drug discovery know-how, compound library and services to add value to our vibrant client network and the pharmaceutical R&D community.
Through this we help you accelerate drug discovery for a healthier society.
PPSC is located at Pivot Park in the Netherlands, which focuses on pharmaceutical R&D. It is an inspiring campus for open innovation in life sciences.
✔ Integrated approach for early drug discovery
✔ Rapid generation of high-quality hits;
All major read-out modalities available in-house including MALDI-TOF MS
✔ Handling of large customer compound libraries;
bring your own library or use our 300k in-house compound library
✔ Big pharma-like uHTS set-up and top-notch read-out technologies
✔ Very experienced screening site for ELF & pharma-accounts
✔ Broad knowledge in different assay development-solutions
✔ From disease targets to high-quality starting points for drug development
Interested? Get in touch and we’ll help you accelerate your drug discovery.
Mass Spectrometry methods in High Throughput Screening
Maaike Bras, scientist assay development at Pivot Park Screening Centre, joined in the Lab of the Future series from SLAS
Oss, the Netherlands – 9 March 2023 The project looked for compounds that stop the virus’s spike protein from binding
We started a program to identify novel hits that inhibit the interaction between the viral spike protein subunit S1 and human angiotensin-converting enzyme 2 (hACE2).
SLAS Europe 2023: Science set in motion
The SLAS 2022 AI-Powered Drug Discovery Symposium brings us to the United Stated! Will we see you there?
Is your assay amendable to ultra-High-Throughput Screening?
Seven aspects to consider…
Subscribe to our newsletter
Pivot Park – Banting Building (RE2423)
Kloosterstraat 9
5349 AB Oss
The Netherlands
Pivot Park Screening Centre
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
To download this publication we would like to receive your e-mail.
To download this publication we would like to receive your e-mail.
To download this publication we would like to receive your e-mail.
